The Origin, Prevalence, Diagnosis and Treatment of COVID-19: An Overview
Keywords:COVID-19, Vaccines, WHO, SARS-CoV-2, Viruses, Pandemic and vaccine
The outbreak of COVID-19 was emerged initially in Wuhan, Hubei province of China in December 2019 then quickly spread throughout the world. The World Health Organization (WHO) confirmed it a public health emergency of global concern and is causing cumulative alarm. The International Committee on Taxonomy of Viruses (ICTV) named acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 virus is composed of ssRNA having 60-120 nm of genomic diameter. It has high infection ability and a low mortality rate then (SARS-CoV and MERS-CoV). Now a vaccine has been developed for the treatment of COVID-19. The prevention of existing viruses must be followed by WHO guidance i.e. social separation, washing hands regularly, disinfecting use in the workplace and home. Here we summarize the origin, prevalence, diagnosis, treatments, as well listed of vaccines against the COVID-19 virus. The main aim of the current review article comprises data obtained from current research papers and WHO recommendations to prevention, care, trial with a new investigation of research, treatment, an invention of updated vaccines, and provide bibliophiles through the present information on the emerging contagious outbreak.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 395:497–506. https://doi.org/10.1016/ S0140-6736(20)30183-5
Liu Y, Gayle A. A, Wilder-Smith A, Rocklov J. 2020. The reproductive number of COVID-19 is higher compared to SARS coronavirus. J. Travel. Med. 27(2):taaa021. https://doi.org/ 10.1093/jtm/taaa021
Xiao Y. et al. March 17, 2020. Prevention of SARS-CoV-2 infection in patients with decompensated cirrhosis. Lancet. Gastroenterol. Hepatol. 1253 (20): 30080–30087.
Wang P, Anderson N, Pan Y, Poon L, Charlton C, Zelyas N, & Babcock H. 2020. The SARS-CoV-2 outbreak: diagnosis, infection prevention, and public perception. Clin. chem. 66(5): 644-651.
Update C. Masks And Temperature Checks In Hong Kong. Nevada Public Radio. (2020).
Marsh S. Four cruise ship passengers test positive in UK–as it happened. The Guardian. (2020).
Nikel D. 2020. Denmark closes border to all international tourists for one month. Forbes. Retrieved 13 March 2020.
Jernigan D. B, COVID C, & Team R. 2020. Update: public health response to the coronavirus disease 2019 outbreak—United States, February 24, 2020. Morbidity and mortality weekly report. 69(8): 216.
Deerwester J, & Gilbertson D. 2020. Coronavirus: US says' do not travel'to Wuhan, China, as airlines issue waivers, add safeguards. USA Today. Archived from the original on, 27. (2020).
Chan J. F, To K. K, Tse H, Jin D. Y, Yuen K. Y. 2013. Interspecies transmission and emergence of novel viruses: lessons from bats and birds. Trends. Microbiol. 21:544–55.
Zhu N, Zhang D, Wang W, Li X, Yang, Song J, et al. 2020. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 2020;382(8):727–33.
Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P, et al. 2020. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe. 27(3):325–8.
Hoffmann M, Kleine-Weber H, Krüger N, Müller M, Drosten C, Pöhlmann S. 2020. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. bioRxiv. 2020.01.31.929042.
Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. 2020. Cry-o-EM structure of the 2019-nCoV spike in the prefusion conformation. Science (New York, NY). 367(6483):1260–3.
Zhou P, Yang X L, Wang X. G, Hu B, Zhang L, Zhang W & Shi Z. L. 2020. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 579(7798): 270-273.
Hu B, Zeng L. P, Yang X. L, Ge X. Y, Zhang W, Li B, & Shi Z. L. 2017. Discovery of a rich gene pool of bat SARS-related coronaviruses provides new insights into the origin of SARS coronavirus. PLoS. Pathog. 13(11): e1006698.
Cunningham C. H, & Stuart H. O. 1947. Cultivation of the virus of infectious bronchitis of chickens in embryonated chicken eggs. Am. J. Vet. Res. 8(27): 209-212.
Binn L. N, Lazar E. C, Keenan K. P, Huxsoll D. L, Marchwicki R. H & Strano A. J. 1974. Recovery and characterization of a coronavirus from military dogs with diarrhea. In Proceedings, Annual Meeting of the United States Animal Health Association (1974, December). (No. 78).
Corman V. M, Baldwin H. J, Tateno A. F, Zerbinati R. M, Annan A, Owusu M, & Drexler J. F. 2015. Evidence for an ancestral association of human coronavirus 229E with bats. J. Virol. 89(23):11858-11870.
Pfefferle S, Oppong,S, Drexler J. F, Gloza-Rausch F, Ipsen A, Seebens A, & Drosten C. 2009. Distant relatives of severe acute respiratory syndrome coronavirus and close relatives of human coronavirus 229E in bats, Ghana. Emerg. Infect. Dis. 15(9): 1377.
Pfefferle S, Oppong S, Drexler J. F, Gloza-Rausch F, Ipsen A, Seebens A. et al. 2010. Metagenomic analysis of the viromes of three North American bat species: viral diversity among different bat species that share a common habitat. J. Virol. 84 (24): 13004-13018.
Li X, Song Y, Wong G, & Cui J. 2020. Bat origin of a new human coronavirus: there and back again. Sci China. Life. Sci. 63(3): 461-462.
Alanagreh L. A, Alzoughool F & Atoum M. 2020. The human coronavirus disease COVID-19: its origin, characteristics, and insights into potential drugs and its mechanisms. Pathog. 9 (5): 331.
Remais J. 2010. Modelling environmentally-mediated infectious diseases of humans: transmission dynamics of schistosomiasis in China. Modelling parasite transmission and control 2010: 79-98.
Wu J. T, Leung K. & Leung G. M. 2020. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. The Lancet. 395 (10225): 689-697.
Majumder M. & Mandl K. D. 2020. Early transmissibility assessment of a novel coronavirus in Wuhan. Available at SSRN 2020.
Lipsitch M, Cohen T, Cooper B, Robins J. M, Ma S, James L, & Murray M. 2003. Transmission dynamics and control of severe acute respiratory syndrome. Sci. 300(5627): 1966-1970.
Majumder M. S, Rivers C, Lofgren E, & Fisman D. 2014. Estimation of MERS-coronavirus reproductive number and case fatality rate for the spring 2014 Saudi Arabia outbreak: insights from publicly available data. PLo.S Curr. 2014: 6.
Guan W. J, Ni Z. Y, Hu Y, Liang W. H, Ou C. Q, He J. X & Zhong N. S. 2020. Clinical characteristics of 2019 novel coronavirus infection in China. MedRxiv. (2020).
Wu Z, & McGoogan J. M. 2020. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. Jama. 323(13): 1239-1242.
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, & Zhang L. 2020. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The lancet. 395 (10223): 507-513.
Bauch C. T & Oraby T. 2013. Assessing the pandemic potential of MERS-CoV. The Lancet. 382(9893): 662-664.
Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W & Zhang Y. 2020. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. The lancet. 395 (10226): 809-815.
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J & Peng Z. 2020. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. Jama. 323 (11): 1061-1069.
Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y & Feng Z. 2020. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. New. Eng. J. Med. (2020).
Peiris J. S. M, Guan Y & Yuen K. 2004. Severe acute respiratory syndrome. Nature. Med. 10(12): S88-S97.
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, & Tan W. 2020. A novel coronavirus from patients with pneumonia in China, 2019. New. Eng. J. Med. (2020).
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, & Cao B. 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet. 395 (10223): 497-506.
Ahmed S. S. 2020. The Coronavirus disease 2019 (COVID-19): a review. J. Adv Med. Med. Res. 2020:1-9.
Available:https://www.forbes.com/sites/liset tevoytko/2020/01/30/coronavirus-1st-us-human-to-human-transmission-confirmed-rightbefore-whoemergencymeeting/#74479b63fcac(Assessed on 02 Feb 2020).
Hui DS, Azhar EI, Madani TA, Ntoumi F, Kock R, Dar O & Petersen E. 2020. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health—The latest 2019 novel coronavirus outbreak in Wuhan, China. Inter J. Infect. Dis. 91 2020: 264-266.
Parry J. 2020. China coronavirus: cases surge as official admits human to human transmission (2020).
Corman V. M, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu D. K & Drosten C. 2020. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Eurosurveillance. 25 (3): 2000045.
Chu D. K, Pan Y, Cheng S. M, Hui K. P, Krishnan P, Liu Y, & Poon L. L. 2020. Molecular diagnosis of a novel coronavirus (2019-nCoV) causing an outbreak of pneumonia. Clin. Chem. 66 (4): 549-555.
Chan J. F. W, Yuan S, Kok K. H, To K. K. W, Chu H, Yang J, & Yuen K. Y. 2020. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. The lancet. 395 (10223): 514-523.
To K. K. W, Tsang O. T. Y, Yip C. C. Y, Chan K. H, Wu T. C, Chan J. M. C & Yuen K. Y. 2020. Consistent detection of 2019 novel coronavirus in saliva. Clin. Infect. Dise. 71 (15): 841-843.
Wang S. S, Zhou X, Lin X. G, Liu Y. Y, Wu J. L, Sharifu L. M, & Feng L. 2020. Experience of clinical management for pregnant women and newborns with novel coronavirus pneumonia in Tongji Hospital, China. Curr Med. Sci. 2020:1-5.
Zhao J. Y, Yan J. Y & Qu J. M. 2020. Interpretations of diagnosis and treatment protocol for novel coronavirus pneumonia (trial version 7). Chinese. Med. J. 133 (11): 1347-1349.
Wang L, Wang Y, Ye D & Liu Q. 2020. Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence. Inter. J. Antimicrob. Agen. 55 (6): 105948.
Di L, Fu Y, Sun Y, Li J, Liu L, Yao J, & Wang J. 2020. RNA sequencing by direct tagmentation of RNA/DNA hybrids. PNAS. 117(6): 2886-2893.
McCreary E. K Pogue J. M. 2020. on behalf of the Society of Infectious Diseases Pharmacists. COVID-19 Treatment: a review of early and emerging options. In Open. Forum. Infect. Dis. 2020: (Vol. 7)
O'Keefe B. R, Giomarelli B, Barnard D. L, Shenoy S. R, Chan P. K, McMahon J. B, & McCray P. B. 2010. Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family Coronaviridae. J. Virol. 84 (5): 2511-2521.
Arabi Y. M, Shalhoub S, Mandourah Y, Al-Hameed F, Al-Omari A, Al Qasim E, & Fowler R. 2020. Ribavirin and interferon therapy for critically ill patients with middle east respiratory syndrome: a multicenter observational study. Clin Infect Dis. 70 (9): 1837-1844.
Siegel D, Hui H. C, Doerffler E, Clarke M. O, Chun K, Zhang L, & Mackman R. L. 2017. Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo [2, 1-f][triazin-4-amino] adenine C-nucleoside (GS-5734) for the treatment of Ebola and emerging viruses (2017).
WHOQ & A on coronaviruses (COVID-19). https://www.who. int/newsroom/q-a-detail/q a-coronaviruses
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, & Peng Z. 2020. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. Jama. 323 (11): 1061-1069.
Russell C. D, Millar J. E & Baillie J. K. 2020. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. The Lancet. 395 (10223): 473-475.
Zhao J. P, Hu Y, Du R. H, Chen Z. S, Jin Y, Zhou M, & Cao B. 2020. Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia. Zhonghua jie he he hu xi za zhi= Zhonghua jiehe he huxi zazhi= Chinese. J. Tubercul. Resp. Dis. 43 (3): 183-184.
Huang R, Zhu L, Xue L, Liu L, Yan X, Wang J, & Wu C. 2020. Clinical findings ofpatients with coronavirus disease 2019 in Jiangsu province, China: A retrospective, multi-center study. PLOS. Negl. Trop. Dis. 14 (5): e0008280.
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, & Zhang L. 2020. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The lancet. 395(10223): 507-513.
Lim J, Jeon S, Shin H. Y, Kim M. J, Seong Y. M, Lee W. J, & Park S. J. 2020. Case of the Index Patient Who Caused Tertiary Transmission of COVID-19 Infection in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Infected Pneumonia Monitored by Quantitative RT-PCR. J. Korean. Med. Sci. 35 (6) e79-e79.
Lim J, Jeon S, Shin H. Y, Kim M. J, Seong Y. M, Lee W. J, & Park S. J. 2020. The author's response: case of the index patient who caused tertiary transmission of coronavirus disease 2019 in Korea: the application of Lopinavir/Ritonavir for the treatment of COVID-19 pneumonia monitored by quantitative RT-PCR. J. Korean Med. Sci. 35 (7) e89.
Prajapat M, Sarma P, Shekhar N, Avti P, Sinha S, Kaur H, & Medhi B. 2020. Drug targets for corona virus: A systematic review. Indian J. Pharma. 52(1): 56.
Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, & Wang, C. 2020. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. New Eng. J. Med. (2020).
Dong L, Hu S, & Gao J. 2020. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov. Thera. 14 (1): 58-60.
Biggioggero M, Crotti C, Becciolini A, & Favalli E. G. 2019. Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection. Drug. Des. Devel. Ther. 13: 57.
Holshue M. L, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, & Pillai S. K. 2020. First case of 2019 novel coronavirus in the United States. New Engl. J. Med.
Jin YH, Cai L, Cheng ZS, Cheng H, Deng T, Fan Y. P, & Wang X. H. 2020. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Military. Med. Res. 7 (1): 1-23.
Zhang L, & Liu Y. 2020. Potential interventions for novel coronavirus in China: A systematic review. J. Med. Virol. 92 (5) 479-490.
Jie Z, He H, Xi H, & Zhi Z. 2020. Multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia. Expert Consensus on Chloroquine Phosphate for the Treatment of Novel Coronavirus Pneumonia [in Chinese] 10: 1001-0939.
Dutta A. K. 2020. Vaccine Against Covid-19 Disease–Present Status of Development. Indian J. Pediatrics. 2020: 1-7.
World Health Organization. Covid-19 vaccines: safety surveillance manual (2020).
Khatiwada A. P, Shrestha N, & Shrestha S. 2021. Will COVID-19 Lead to a Resurgence of Vaccine-Preventable Diseases?. Infect. Drug Resist. 14, 119.
World Health Organization Draft landscape and tracker of COVID-19 candidate vaccines. World Health Organization: Genova, Switzerland (2021).
Craven J. RAPS: COVID-19 vaccine tracker. https://www.raps. org/news-and-articles/news-articles/2020/3/covid-19-vaccinetracker (2021). Accessed 22 May 2021.
Ella R, Reddy S, Jogdand H, Sarangi V, Ganneru B, Prasad S, & Vadrevu K. M. 2021. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. The Lancet Infectious Diseases (2021).
Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, & Hamlyn J. 2020. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. The Lancet. 396(10249): 467-478.
Jackson L. A, Anderson E. J, Rouphael N. G, Roberts P. C, Makhene M, Coler R. N & Beigel J. H.2020. An mRNA vaccine against SARS-CoV-2—preliminary report. New Engl. J. Med. (2020).
Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S & Glenn GM. Phase 1–2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. New Engl J. of Med. 383 (24): 2320-2332.
Logunov D. Y, Dolzhikova I. V, Zubkova O. V, Tukhvatullin A. I, Shcheblyakov D. V, Dzharullaeva A. S, & Gintsburg A. L. 2020. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. The Lancet. 396(10255): 887-897.
Mulligan M. J, Lyke K. E, Kitchin N, Absalon J, Gurtman A, Lockhart S, & Jansen K. U. 2020. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 586 (7830): 589-593.
Polack F. P, Thomas S. J, Kitchin N, Absalon J, Gurtman A, Lockhart S, & Gruber W. C. 2020. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New Engl. J. Med.383 (27): 2603-2615.
Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, de Groot A. M, & Schuitemaker H. 2020. Safety and immunogenicity of the Ad26. COV2. S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial. MedRxiv. (2020).
Voysey M, Clemens S. A. C, Madhi S. A, Weckx LY, Folegatti P. M, Aley P. K, & Bijker E. 2021. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet. 397(10269) 99-111.
Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, & Yang X. 2020. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. Jama. 324 (10): 951-960.
Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao G. F, & Yang X. 2021. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. The Lancet Infectious Dis. 21(1): 39-51.
Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, & Zhu F. 2021. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet. Infect. Dis. 21 (2): 181-192.
Zhu F. C, Guan X. H, Li Y. H, Huang J. Y, Jiang T, Hou L. H, & Chen, W. 2020. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet. 396 (10249): 479-488.
Zhu F. C et al. 2020. Immunogenicity and safety of a recombinant adenovirus type-5vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 396: 479–488.
Logunov D. Y, Dolzhikova I. V, Zubkova O. V, Tukhvatullin A. I, Shcheblyakov D. V, Dzharullaeva A. S, & Gintsburg A. L. 2020. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. The Lancet. 396 (10255): 887-897.
Folegatti P. M, Ewer K. J, Aley P. K, Angus B, Becker S, Belij-Rammerstorfer S, & Hamlyn J. 2020. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. The Lancet. 396 (10249): 467-478.
Xia S, Duan, K, Zhang Y, Zhao D, Zhang H, Xie Z, & Yang X. 2020. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. Jama. 324 (10), 951-960.
Jackson L. A, Anderson E. J, Rouphael N. G, Roberts P. C, Makhene M, Coler R. N, & Beigel J. H. 2020. An mRNA vaccine against SARS-CoV-2—preliminary report. New Eng. J. Med.
Anderson E. J, Rouphael N. G, Widge A. T, Jackson L. A, Roberts P. C, Makhene M, & Beigel J. H. 2020. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. New Engl. J. Med. 383 (25): 2427-2438.
Mulligan M. J, Lyke K. E, Kitchin N, Absalon J, Gurtman A, Lockhart S, & Jansen K. U. 2020. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 586 (7830): 589-593.
Walsh E. E, Frenck R, Falsey A.R, Kitchin N, Absalon J, Gurtman A, & Gruber W. C. 2020. RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study. Medrxiv.
How to Cite
Copyright (c) 2021 Mahideen Afridi, Khurshid Ahmad, Nasir Ali Khan, Abid Khan, Feifei Wang, Faiza Yaseen
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
- Papers must be submitted on the understanding that they have not been published elsewhere (except in the form of an abstract or as part of a published lecture, review, or thesis) and are not currently under consideration by another journal published by any other publisher.
- It is also the authors responsibility to ensure that the articles emanating from a particular source are submitted with the necessary approval.
- The authors warrant that the paper is original and that he/she is the author of the paper, except for material that is clearly identified as to its original source, with permission notices from the copyright owners where required.
- The authors ensure that all the references carefully and they are accurate in the text as well as in the list of references (and vice versa).
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Attribution-NonCommercial 4.0 International that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
- The journal/publisher is not responsible for subsequent uses of the work. It is the author's responsibility to bring an infringement action if so desired by the author.